Abstract
Infographic titled "The six-minute walk test in transthyretin cardiac amyloidosis - prognostic utility put to the real-world test." It presents data from 252 ATTR-CM patients, mostly male, studied from March 2012 to July 2024. The middle section illustrates the six-minute walk test progress over three years, with a Kaplan-Meier survival plot. The right section shows threshold hazard ratios for distances below 350 meters. Key findings are listed below, emphasizing the test's prognostic value but not for patients on amyloid-specific therapy.